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Objectives The purpose of this study was to examine the feasibility of repeated pulmonary artery (PA) pressure determina-
tions using a newly developed acoustic wireless implanted communication system.
Background Congestive heart failure management strategies based on monitored intracardiac hemodynamics in patients
receiving the best-available therapy may improve outcome. Although electromagnetic communication requires
a large antenna for sufficient energy transfer, acoustic energy readily penetrates deep into the body, uses little
energy, and uses small internal transducers for bidirectional operation.
Methods A miniature device was developed and implanted using right heart catheterization. The ability to obtain PA pres-
sure from the implant using wireless acoustic communication was examined in 8 pigs and 10 patients with con-
gestive heart failure. Macroscopic and histopathologic examinations were performed at 6 months after implan-
tation. The accuracy of PA pressure measurement was determined by comparison with simultaneous pressures
from a Millar catheter.
Results The device was successfully implanted in the PA using right heart catheterization. There were no implantation
or later device-related complications. Pulmonary artery pressure tracings were repeatedly obtained from all im-
plants. Normal reactions to intravascular implant were observed macroscopically and in histologic sections.
Standard deviations of the difference between implant and Millar PA diastolic pressure were 1.45 and 1.2
mm Hg (animals and humans, respectively). Data were useful for patient management.
Conclusions This pilot study demonstrates, for the first time, that acoustic wireless communication with a miniature im-
planted sensor is feasible and provides repeated PA pressure measurement. This feat makes possible mul-
tiple novel applications for monitoring and therapeutic interventions based on measurements from deeply
implanted devices. (J Am Coll Cardiol 2007;49:784–9) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.021w
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songestive heart failure (CHF) is a major cause of mortal-
ty, morbidity, and hospitalization worldwide (1). Effective
herapy is available (2), and care using disease-management
ystems improves outcomes (3,4). Although heart cathe-
erization is the most accurate way to define hemody-
amic state, its invasive nature limits its use to patients
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mployee of Remon Medical Technologies. Dr. Schwartz is a consultant to Remon
edical Technologies.b
Manuscript received May 22, 2006; revised manuscript received October 3, 2006,
ccepted October 9, 2006.ith severe decompensation (5). The noninvasive detec-
ion of hemodynamic abnormalities before clinical dete-
ioration occurs might be helpful to improve care (6,7). A
ecent study (unpublished data, COMPASS Investiga-
ors, March 2005) demonstrated that CHF management
ased on continuously monitored intracardiac pressures
n patients already receiving the best-available therapy
mproves outcome.
Clinically available monitoring systems for heart disease
se electromagnetic energy to communicate with cardiac
ensors (6–8). Limited energy penetration mandates a wire
e used to transmit the signal from the sensor to the body
urface. Acoustic energy is not substantially attenuated by
ody tissue, making wireless communication feasible. This
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February 20, 2007:784–9 Wireless Telemetry of Pulmonary Artery Pressuretudy describes a wireless pulmonary artery (PA) pressure
easurement system comprising a miniature PA device
mplant using right heart catheterization.
ethods
ressure-monitoring system. The system comprises an
mplant and an external communication/analysis unit (Re-
on Medical Technologies/Inc., Waltham, Massachusetts)
Fig. 1). The implant is housed in a titanium case measuring
 1.5  16 mm. The case contains a pressure sensor, a
iezoelectric internal transducer, and a custom-built, low-
ower control chip. The transducer is omnidirectional
ecause its dimension is much less than the operating
avelength. A self-expanding nitinol anchor adapts to 15-
o 25-mm vessel diameters for vessel wall fixation. An
xternal unit transmits and receives signals from the implant
ia a transducer in bodily contact. This unit includes a
ressure sensor for converting absolute into gauge pressure.
hen interrogated by the external unit, the implant is
ctivated, charged, and subsequently measures pressure and
ransmit full pressure waveforms for 5 to 10 s.
mplantation procedure. The implant is designed for the
uman proximal right PA. This segment is located behind
he ascending aorta, providing for minimal acoustic energy
ttenuation by the air–water interface. A 10-F introducer
heath is advanced to the PA using standard technique, and
pulmonary angiogram is obtained. The optimal implant
ite is determined by anatomy and vessel size; the sheath is
dvanced to this site, and the implant is delivered like a
elf-expandable stent.
Anatomic differences between pigs and humans necessi-
ated device deployment in the angulated distal main PA
egment in the animal study. Although this location is
Figure 1 Pressure-Monitoring System
The system comprises an implant (A) and an external communication/analysis unuitable for acoustic communica-
ion, it has limitations for de-
loying the nitinol anchor. The
nchor was expanded in the
urved main PA segment, in-
luding the bifurcation in some
ases. The animal studies were
sed to evaluate implant histopathology in addition to
ensor and communication performance but were subopti-
al for the examination of anchor design.
nimal studies. Eight domestic pigs (55 to 60 kg) under-
ent evaluation. Animals were given 100 U/kg heparin
uring catheterization and 100 mg aspirin/75 mg clopi-
ogrel daily for the month after the implant. Invasive
emodynamic assessments were performed immediately
fter implantation and at 3 and 6 months. A Millar catheter
Millar Instruments Inc., Houston, Texas) was advanced to
he PA, and simultaneous pressures obtained for direct
omparison. Animals were euthanized by lethal barbiturate
njection 17 or 26 weeks (n  1 and 7, respectively) after
mplantation. At autopsy, the implant site was carefully
xamined and the lungs examined for thromboembolism.
ections (20 m) were obtained from implant and stained
ith modified Paragon staining. Lung samples were stained
ith hematoxylin-eosin-safranin.
uman studies. Patients with class III or IV CHF were
pproached for study participation at the Apollo Hospital
Gandhinagar, India). Patients were excluded for pace-
akers, creatinine 2.5 mg/dl, and expected survival 6
onths. The study was approved by the institutional review
oard of the Apollo Hospital, and patients signed informed
onsent before the procedure. Demographic parameters
ere recorded, including age, gender, New York Heart
ssociation functional class, and left ventricular ejection
Abbreviations
and Acronyms
CHF  congestive heart
failure
PA  pulmonary arteryit (B).
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Wireless Telemetry of Pulmonary Artery Pressure February 20, 2007:784–9raction. Simultaneous implant PA and Millar catheter
ressure are reported at the implant time.
tatistical analysis. Diastolic and PA pulse pressure at
ach implant interrogation were calculated as the mean
alue obtained during 5 to 10 s of simultaneous waveform
ecording. In cases with marked respiratory variation, end
xpiratory values were used. Regression analysis and the Bland-
ltman method (9) compared implant and Millar pressures.
esults
reclinical data. Device implantation was successful in all
igs. There were no adverse clinical events at implantation
r afterwards, until euthanasia. Fluoroscopy and macro-
copic observation verified that the implant was at the
esired location in all animals (Figs. 2 and 3). Anchor struts
n contact with the vessel wall were covered by a thin
eointimal tissue (Fig. 3). Because implants were located
lose to or within the PA bifurcation, some struts were free
n the arterial lumen and were not covered by tissue. This
nding was expected based on limitations of pig anatomy
Fig. 2). Limited neointimal thickening was observed
round the anchor and titanium box, without luminal
arrowing, and there was no degradation of the box (Figs.
C and 3D). No thrombi occurred in any lung section.
ulmonary artery pressures were easily obtained from all
mplants. Table 1 summarizes simultaneous diastolic and
Figure 2 Angiographic Images During Device Implantation
(A) Human right pulmonary angiogram. (B) Angiography of the pig main pulmonary
artery. Panels C and D are fluoroscopic images of the human and pig implants, reulse PA pressures from the implant and Millar catheter
t times 0, 3, and 6 months. Follow-up pressure readings
emained as accurate as at implant, and there were no
ystematic changes over time to suggest sensor drift.
tandard deviations of the difference between implant
nd Millar recordings were 1.45 and 1.16 mm Hg
diastolic and pulse PA pressures, respectively) (Fig. 4).
his difference is within the error limit of the Millar
atheter (2 mm Hg).
uman data. Eleven patients with CHF were enrolled in
he study. Age ranged from 25 to 58 years (mean 44.6
ears), and 10 of the patients were men. Left ventricular
jection fraction range was 20% to 32% (mean 28%). Six
atients were identified as New York Heart Association
unctional class III. Pulmonary angiography was performed,
nd the implant landing zone was determined (Figs. 2A and
C). Implantation was successful in 10 patients (1 patient
as excluded after pulmonary angiography revealed a PA
iameter 25 mm). Deployment was coaxial in 8 patients,
hereas in the other 2, the implant was rotated in the artery
ecause of right upper lobe branch involvement. Part of the
mplant (in these 2 patients) remained in that branch, but
here was no pulmonary flow limitation. Patients were
ischarged 1 day after the procedure. No device-related
omplications occurred during the following 6 months.
ressure measurements were successfully obtained from all
mplants. Figures 5A and 5B are typical pressure recordings
vely.specti
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February 20, 2007:784–9 Wireless Telemetry of Pulmonary Artery Pressurend Figures 5C and 5D summarize the comparison of the
mplant and Millar pressure values.
Figure 6 shows a patient in whom the implanted device was
linically useful. This patient had idiopathic dilated cardiomy-
pathy and was clinically stable for 2 months, with PA
iastolic pressures of 9 to 13 mm Hg. She was subsequently
dmitted to the hospital complaining of cough and short-
ess of breath. A clinical diagnosis of viral infection was
ade but was changed to acute CHF exacerbation when
mplant interrogation revealed a diastolic PA pressure of 45
m Hg. She was given a diuretic, the PA diastolic pressure
ecreased to 15 mm Hg, and she rapidly improved.
Figure 3 Macroscopic View and Histologic Sections of the Imp
(A) Fluoroscopy of the implant in situ, after sacrifice. (B) Macroscopic view of the
pulmonary artery. Panels C and D are histologic sections at the level of the titaniu
Summary of the Differences Between Implant anReadings (in mm Hg) in the Studi d Animals (B
Table 1 Summary of the Differences BetweeReadings (in mm Hg) in the Studied
Baseline
Diastolic
Pressure
Pulse
Pressure
Mean difference 1.74 0.26
SD 1.12 1.03
Lower limit 3.24 3.44Upper limit 0.91 1.20 1iscussion
reclinical and human data in this pilot study show that PA
ressure can be repeatedly measured by wireless acoustic
elemetry using a miniature device in the PA. Device
mplant is a simple right heart catheterization procedure.
he device was functional and accurate for 6 months and
ustained no damage from biologic processes.
Wireless communication by electromagnetic energy re-
uires a large antenna and, thus, is not suitable for deep
ody implants. Long-term bidirectional electromagnetic
ommunication is prohibitive because of large power re-
fter 6 Months
t in the main
e and the anchor, respectively.
llar Pressuretman Method)
plant and Millar Pressure
als (Bland-Altman Method)
3 Months 6 Months
tolic
sure
Pulse
Pressure
Diastolic
Pressure
Pulse
Pressure
.1 0.3 0.21 0.79
.06 0.95 1.56 1.50
.11 1.94 2.51 4.37lant A
implan
m casd Miland-A
n Im
Anim
Dias
Pres
0
1
2.06 0.95 2.91 1.19
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Wireless Telemetry of Pulmonary Artery Pressure February 20, 2007:784–9uirements, typically several milliwatts. Acoustic energy in
he kHz frequency range penetrates deep into the body
sing little energy (tens of nanowatts) and uses small
nternal transducers (approximately 1 mm). This energy is
afe because acoustic pressure is 10 kPa, much lower than
ypical pressures in diagnostic ultrasound.
Several other implantable systems are under evaluation to
onitor patients with heart disease. Intracardiac pressure
nd pulmonary fluid volume are used to detect early dete-
ioration of CHF (6,7), and intramyocardial electrocardiog-
aphy can detect rejection after cardiac transplantation (8).
wire is required for data transfer to a superficially
mplanted module, similar to a pacemaker, which is inter-
ogated using electromagnetic communication. The advan-
ages of a wireless system are obvious and expand the clinical
tility of telemetric systems. The implant is much smaller;
mplantation is simple and minimally invasive. Also, wire-
ess intrabody communication among multiple miniature
mplants is feasible using acoustic energy. The unique
eatures of this system enable easy adaptation to other
pplications.
Our device is designed for use in CHF. Management of
hese patients still requires frequent hospital admission,
ith high morbidity and mortality. Telemetric monitoring
f simple vital signs improves care (10), and adding teleme-
ered intracardiac pressure provides a quantum improve-
Figure 4 Bland-Altman Comparison of PA
Pressures From the Implant and the Millar Catheter
Diastolic and pulse pulmonary artery (PA) pressures (A and B, respectively).ent (7). The implanted programmable memory providesight ventricular pressure from which diastolic PA pressure
an only be estimated. Reynolds et al. (11) validated the
stimation algorithm and Magalski et al. (12) demonstrated
hat the sensor remained stable for more than 1 year. Estimat-
Figure 5 PA Pressure Measurements in Humans
Panels A and B are typical waveforms obtained simultaneously from the Millar
catheter and the implant. Note the respiratory variation in panel B. Panels C
and D are Bland-Altman and linear regression comparisons (respectively) of
implant and Millar pulmonary artery (PA) diastolic pressures.
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February 20, 2007:784–9 Wireless Telemetry of Pulmonary Artery Pressureng PA diastolic pressure from right ventricular pressure is not
s accurate as direct measurement: a 5-mm Hg difference
rom control using the estimated value and only a 1.2-mm
Figure 6 Congestive Heart Failure Decompensation (Example)
(A and B) Regular follow-up while the patient was clinically stable; (C) during
admission; (D) after diuretic therapy. PA  pulmonary artery; PAD  pulmonary
artery diastolic pressure.g with direct measurement (our human data).tudy limitations. This was a pilot trial. Safety and accu-
acy should be determined in additional trials. The current
esign contains no energy source; therefore, before data
ransmission, the implant must be charged for 30 s. This
evice is thus not suitable for home monitoring. Home
onitoring is essential to detect impending decompensation
y analyzing pressure trends over time (7). Future designs
nclude a miniature battery, which simplifies interrogation
nd makes the system suitable for home monitoring.
onclusions. This study demonstrated that wireless com-
unication with a miniature PA pressure sensor is feasible.
epeated, high-quality PA tracings were easily obtained.
coustic telemetry makes possible multiple novel monitor-
ng and therapeutic interventions based on communication
ith deeply implanted devices in the heart and elsewhere.
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